Trial Profile
A Phase I, Multicenter, Randomized, Double-Blind, Placebo-Controlled Trial of the Safety and Pharmacokinetics of PRO283698 in Patients With Rheumatoid Arthritis.
Status:
Completed
Phase of Trial:
Phase I
Latest Information Update: 26 Nov 2014
Price :
$35
*
At a glance
- Drugs Pateclizumab (Primary) ; Pateclizumab (Primary)
- Indications Rheumatoid arthritis
- Focus Adverse reactions
- Sponsors Genentech
- 09 May 2012 Results presented at the 113th Annual Meeting of the American Society for Clinical Pharmacology and Therapeutics.
- 30 Nov 2010 Actual end date (Jun 2010) added as reported by ClinicalTrials.gov.
- 30 Nov 2010 Status changed from recruiting to completed as reported by ClinicalTrials.gov.